JP2023509214A5 - - Google Patents

Info

Publication number
JP2023509214A5
JP2023509214A5 JP2022542268A JP2022542268A JP2023509214A5 JP 2023509214 A5 JP2023509214 A5 JP 2023509214A5 JP 2022542268 A JP2022542268 A JP 2022542268A JP 2022542268 A JP2022542268 A JP 2022542268A JP 2023509214 A5 JP2023509214 A5 JP 2023509214A5
Authority
JP
Japan
Prior art keywords
seq
sequence shown
chain variable
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509214A (ja
JP7840852B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/070899 external-priority patent/WO2021139776A1/en
Publication of JP2023509214A publication Critical patent/JP2023509214A/ja
Publication of JP2023509214A5 publication Critical patent/JP2023509214A5/ja
Application granted granted Critical
Publication of JP7840852B2 publication Critical patent/JP7840852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542268A 2020-01-10 2021-01-08 抗tigit抗体、それを含む多重特異性抗体及びその使用方法 Active JP7840852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/071340 2020-01-10
CN2020071340 2020-01-10
PCT/CN2021/070899 WO2021139776A1 (en) 2020-01-10 2021-01-08 Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same

Publications (3)

Publication Number Publication Date
JP2023509214A JP2023509214A (ja) 2023-03-07
JP2023509214A5 true JP2023509214A5 (cg-RX-API-DMAC7.html) 2024-01-16
JP7840852B2 JP7840852B2 (ja) 2026-04-06

Family

ID=76787748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542268A Active JP7840852B2 (ja) 2020-01-10 2021-01-08 抗tigit抗体、それを含む多重特異性抗体及びその使用方法

Country Status (10)

Country Link
US (1) US12415858B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087862A4 (cg-RX-API-DMAC7.html)
JP (1) JP7840852B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131260A (cg-RX-API-DMAC7.html)
CN (1) CN115066431B (cg-RX-API-DMAC7.html)
AU (1) AU2021205565B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022013298A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164283A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021139776A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208798B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818795B (zh) * 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
WO2022268168A1 (zh) * 2021-06-23 2022-12-29 迈威(上海)生物科技股份有限公司 靶向lag-3和pd-l1的新型双特异抗体及其应用
CN120590537A (zh) * 2021-12-31 2025-09-05 南京维立志博生物科技股份有限公司 靶向tigit的双特异性抗体
TW202417512A (zh) * 2022-10-17 2024-05-01 英屬開曼群島商百濟神州有限公司 含有抗tigit抗體的配製物及其使用方法
WO2025170315A1 (ko) * 2024-02-05 2025-08-14 주식회사 트리오어 이중 기능 도메인을 포함하는 융합단백질 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
US10544222B2 (en) * 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
KR102379464B1 (ko) * 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3565839A4 (en) * 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
US11673954B2 (en) 2017-11-17 2023-06-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-L1
CN109966487B (zh) * 2017-12-28 2023-08-25 上海复宏汉霖生物制药有限公司 一种包含抗pd-l1单克隆抗体的药物配制剂
SG11202004521QA (en) * 2018-02-06 2020-06-29 I Mab Biopharma Us Ltd Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
CN110818795B (zh) * 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法

Similar Documents

Publication Publication Date Title
JP2023509196A5 (cg-RX-API-DMAC7.html)
JP2022101693A5 (cg-RX-API-DMAC7.html)
JP2023522229A5 (cg-RX-API-DMAC7.html)
JP2023509215A5 (cg-RX-API-DMAC7.html)
JP2020513791A5 (cg-RX-API-DMAC7.html)
US10519236B2 (en) Antibodies specific to delta 1 chain of T cell receptor
JP2021501162A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2022516503A5 (cg-RX-API-DMAC7.html)
JP2024056687A5 (cg-RX-API-DMAC7.html)
JP2015509947A5 (cg-RX-API-DMAC7.html)
JP2022516881A5 (cg-RX-API-DMAC7.html)
JP2016536020A5 (cg-RX-API-DMAC7.html)
JP2024520188A5 (cg-RX-API-DMAC7.html)
JP2024515536A5 (cg-RX-API-DMAC7.html)
JP2016510002A5 (cg-RX-API-DMAC7.html)
JP2016538318A5 (cg-RX-API-DMAC7.html)
JP2015509948A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2017535246A5 (cg-RX-API-DMAC7.html)
JP2017518040A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2021522347A5 (cg-RX-API-DMAC7.html)
JP2024511137A5 (cg-RX-API-DMAC7.html)
JP2022513729A5 (cg-RX-API-DMAC7.html)